Franklin Biotechnology Discovery A (MAPTX) seeks capital appreciation by primarily investing in securities of biotechnology companies and discovery research firms.
This non-diversified fund may invest a substantial portion of assets in equity securities of smaller capitalization companies with a market capitalization of less than $1.5 billion.
Gilead Sciences Inc. (GILD), Celgene Corp. (CELG) and Genzyme Corp. (GENZ) are among the fund’s key holdings.
Franklin Real Estate Securities A (FREEX) was incepted in January 1994. The investment seeks maximize total return.
The fund normally invests most of its assets in equity securities of real estate firms. It may invest up to 20% of assets in equity or debt securities of issuers engaged in businesses whose products and services are closely related to the real estate industry.
Shareholders have to make a minimum initial investment of $50,000 to enter this Zacks#1 Rank (“Strong Buy”) fund. It has an expense ratio of 1.22%.
Templeton Developing Markets A (TEDMX) seeks long-term capital appreciation through investment in securities of emerging economies.
The fund may invest up to 20% of net assets in the securities of issuers in developed market countries. It may also invest in exchange-traded funds to gain exposure to certain segments of the equity markets while maintaining liquidity.
J. Mark Mobius has been lead manager at the fund since October 1991. The fund distributes dividends and capital gains, if any, annually.
